Vasculitis Clinical Trials

97 recruitingLast updated: June 17, 2026

There are 97 actively recruiting vasculitis clinical trials across 31 countries. Studies span Phase 1, Phase 2, Early Phase 1, Phase 3, Phase 4, Not Applicable. Top locations include Paris, France, Cleveland, Ohio, United States, Philadelphia, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


Vasculitis Trials at a Glance

97 actively recruiting trials for vasculitis are listed on ClinicalTrialsFinder across 6 cities in 31 countries. The largest study group is Phase 1 with 22 trials, with the heaviest enrollment activity in Paris, Cleveland, and Philadelphia. Lead sponsors running vasculitis studies include Assistance Publique - Hôpitaux de Paris, China Immunotech (Beijing) Biotechnology Co., Ltd., and University of Pennsylvania.

Browse vasculitis trials by phase

Treatments under study

About Vasculitis Clinical Trials

Looking for clinical trials for Vasculitis? There are currently 24 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Vasculitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Vasculitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 97 trials

Recruiting
Phase 2

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alexion Pharmaceuticals, Inc.75 enrolled78 locationsNCT07160608
Recruiting

Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis

ANCA-associated VasculitisGiant Cell ArteritisTakayasu's Arteritis+2 more
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)4,000 enrolled1 locationNCT02257866
Recruiting
Phase 4

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Amgen300 enrolled79 locationsNCT06072482
Recruiting

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

lichen planusAtopic DermatitisHidradenitis Suppurativa+9 more
Assistance Publique - Hôpitaux de Paris830 enrolled1 locationNCT06599411
Recruiting
Phase 1Phase 2

Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms

StrokeVasculitisAneurysm+1 more
University of California, San Francisco8 enrolled1 locationNCT02638701
Recruiting

EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases

PericarditisRheumatoid ArthritisSarcoidosis+10 more
Assistance Publique - Hôpitaux de Paris5,000 enrolled1 locationNCT07077304
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Rheumatoid ArthritisIdiopathic Inflammatory MyopathiesSystemic Sclerosis+1 more
Nkarta, Inc.240 enrolled17 locationsNCT06733935
Recruiting
Phase 2

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

ANCA Associated Vasculitis (AAV)
Novartis Pharmaceuticals126 enrolled35 locationsNCT06868290
Recruiting
Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled21 locationsNCT06308978
Recruiting
Phase 3

Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

Vasculitis
Amgen20 enrolled32 locationsNCT06321601
Recruiting
Phase 1Phase 2

CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Marcela V. Maus, M.D.,Ph.D.12 enrolled1 locationNCT07388277
Recruiting
Early Phase 1

CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07586267
Recruiting

SysteMic vAsculitis pRognosis and ouTcome

Vasculitis
Fondazione IRCCS Policlinico San Matteo di Pavia300 enrolled1 locationNCT07586137
Recruiting
Phase 2

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Alport SyndromeFocal Segmental GlomerulosclerosisImmunoglobulin A Nephropathy+2 more
Travere Therapeutics, Inc.67 enrolled47 locationsNCT05003986
Recruiting

The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions

VasculitisSystemic Lupus Erthematosus (SLE)Rheumatic Diseases+3 more
McGill University Health Centre/Research Institute of the McGill University Health Centre100 enrolled1 locationNCT07278609
Recruiting
Phase 1

Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube

Diffuse Alveolar HemorrhageAntineutrophil Cytoplasmic Antibody Positive Vasculitis
Mayo Clinic6 enrolled1 locationNCT07556484
Recruiting
Phase 3

BDB-001 Phase III Trial in ANCA-Associated Vasculitis

ANCA Associated Vasculitis (AAV)
Staidson (Beijing) Biopharmaceuticals Co., Ltd300 enrolled60 locationsNCT07168161
Recruiting
Early Phase 1

MTS109 in Patients With Refractory Autoimmune Diseases

Systemic Lupus ErythematosusIdiopathic Inflammatory MyopathiesSystemic Sclerosis (SSc)+2 more
Shanghai Changzheng Hospital15 enrolled1 locationNCT07526350
Recruiting
Phase 1Phase 2

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

Juvenile Myasthenia GravisANCA Associated Vasculitis (AAV)Juvenile Dermatomyositis+1 more
Cartesian Therapeutics50 enrolled2 locationsNCT07089121
Recruiting
Phase 3

Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGranulomatosis With Polyangiitis
Assistance Publique - Hôpitaux de Paris42 enrolled1 locationNCT04871191